BRCA1 and prostate cancer: The combination of vorinostat with olaparib synergistically reduced prostate cancer cell viability, induced apoptosis in DU145 and PC3 prostate carcinoma cells, and suppressed DNA repair as well as DNA repair protein expression (BRCA1 and RAD51) in DU145 cells[52].